Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon α-2b + CO2 Laser for Condylomata Acuminata
NCT06430190Not yet recruiting
- Start
- Jul 2024
- Primary completion
- Jan 2025
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Randomised, open-label trial of peginterferon alfa-2b in condylomata acuminata (3 arms). Primary endpoint: Clinical cure rate at 12 weeks. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
condylomata acuminata
Beyond the preview
Go deeper on NCT06430190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06430190.